Its product pipeline includes FIN-211, TAK-524, and FIN-525, as well as consortia product candidates. CP101 is designed to deliver a complete microbiome, addressing the community-level dysbiosis that characterizes CDI. CP101, consists of a microbial community harvested from rigorously screened healthy donors that is lyophilized and formulated in orally administered capsules designed to release at the appropriate location in the gastrointestinal tract. Its lead product candidate, CP101, is an o rally administered complete microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection (CDI). Its Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. It is engaged in leveraging its Human-First Discovery platform to develop a class of orally administered biological drugs. is a clinical-stage microbiome therapeutics company. Finch Therapeutics, RedHill Biopharma, Evolve Biosystems. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the. #FINCH THERAPEUTICS LICENSE#Exclusive Patent License Agreement by and between CIPAC Limited and Regents of the University of Minnesota, dated as of March 26, 2012, as amended July 10, 2014, October 23, 2014.Finch Therapeutics Group, Inc. Finch Therapeutics is a developer of microbiome-based therapies using a human-first discovery.Exclusive License Agreement by and between Crestovo, LLC and Arizona Science and Technology Enterprises LLC, dated as of July 3, 2017, as amended August 27, 2018.and Millennium Pharmaceuticals, Inc., dated as of October 21, 2019 Amended and Restated Agreement by and between Finch Therapeutics, Inc.and Microbiome Health Research Institute, Inc., dated as of November 19, 2020 Asset Purchase Agreement by and between Finch Therapeutics, Inc.LMIC License Agreement by and between Finch Therapeutics, Inc.and North River II LLC, dated as of December 21, 2015 and North River II LLC, dated as of January 20, 2017 First Amendment to Lease by and between Finch Therapeutics, Inc.2017 Equity Incentive Plan, as amended, and the forms of agreements thereunder.Form of Indemnity Agreement between the registrant and its directors and officers.2021 Equity Incentive Plan and the forms of agreements thereunder.Amended and Restated Executive Employment Agreement by and between the registrant and Zain Kassam, dated as of March 12, 2021, to be effective upon the pricing of this offering.Perry, dated as of March 12, 2021, to be effective upon the pricing of this. Amended and Restated Executive Employment Agreement by and between the registrant and Gregory D.Amended and Restated Executive Employment Agreement by and between the registrant and Mark Smith, dated as of March 12, 2021, to be effective upon the pricing of this offering.Amendment, dated August 9, 2021, to the Amended and Restated Agreement, by and between Finch Therapeutics, Inc.Release Agreement, dated November 4, 2021, by and between Finch Therapeutics Group, Inc.and Marc Blaustein, dated as of September 8, 2021 arbtrn ekacaesium problemwise societarian finch. Executive Employment Agreement by and between Finch Therapeutics Group, Inc. unshirking coelectron syntasis therapeutics antiecclesiastically flourish.and Joseph Vittiglio, dated as of March 12, 2021 Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc.Lease, dated August 3, 2021, by and between Hood Park LLC and Finch Therapeutics, Inc.Amended and Restated Exclusive License Agreement between Regents of the University of Minnesota and Finch Therapeutics Holdings LLC, dated January 28, 2022.2, dated November 12, 2021, to the Amended and Restated Agreement by and between Finch Therapeutics, Inc. and Joseph Vittiglio, dated as of March 18, 2021 1 to the Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and each of its Subsidiaries, the several banks and other financial institutions or. Loan and Security Agreement, dated May 11, 2022, by and among Finch Therapeutics Group, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |